{"id":948945,"date":"2026-04-03T13:11:46","date_gmt":"2026-04-03T17:11:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-aldeyra-therapeutics-inc-nasdaq-aldx-should-contact-wolf-haldenstein-immediately\/"},"modified":"2026-04-03T13:11:46","modified_gmt":"2026-04-03T17:11:46","slug":"shareholders-who-lost-money-in-aldeyra-therapeutics-inc-nasdaq-aldx-should-contact-wolf-haldenstein-immediately","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-aldeyra-therapeutics-inc-nasdaq-aldx-should-contact-wolf-haldenstein-immediately\/","title":{"rendered":"Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately"},"content":{"rendered":"

\nLead Plaintiff Deadline is May 29, 2026
\n<\/h2>\n
\n

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP<\/a> informs investors that a securities fraud class action lawsuit has been filed against Aldeyra Therapeutics, Inc., (\u201cAldeyra\u201d or the “Company”) (NASDAQ: ALDX) on behalf of investors that bought securities between November 3, 2023 and March 16, 2026, inclusive (the \u201cClass Period\u201d).<\/p>\n

\n Investors have until May 29, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.<\/strong>\n <\/p>\n

\n
\n PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION<\/strong>
\n <\/a>\n <\/p>\n

On March 17, 2026, the Company filed with the United States Securities and Exchange Commission (\u201cSEC\u201d) a current report on Form 8-K, announcing receipt of a 2026 Complete Response Letter (\u201cCRL\u201d) stating that there is \u201ca lack of substantial evidence consisting of adequate and well-controlled investigations \u2026 that the drug product will have the effect it <\/em>purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling\u201d<\/em> and that \u201cthe application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.\u201d <\/em><\/p>\n

The CRL also stated that the \u201cinconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings\u201d<\/em> and that \u201cthe totality of evidence from the completed clinical trials does not support the effectiveness of the product.\u201d<\/em><\/p>\n

On this news, the price of Aldeyra stock went down by $2.99, or approximately 70.7%, to close at $1.24 per share on March 17, 2026.<\/p>\n

\n Why <\/strong>
\n
\n Wolf Haldenstein Adler Freeman & Herz LLP?<\/strong>:<\/a>\n <\/p>\n

This illustrious firm,<\/a> founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The law firm<\/a> brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.<\/p>\n

We encourage all investors who have been affected or have information that will assist in our investigation, to contact\u00a0Wolf Haldenstein Adler Freeman & Herz LLP.<\/a><\/p>\n

\n There is no cost or obligation to speak with an attorney.<\/strong>\n <\/p>\n

\n Contact:<\/strong>\n <\/p>\n